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and analgesic effects in patients undergoing 
general anesthesia. it enables precise and rapid 
titration of propofol and remifentanil during 
surgery.1 reducing the intraoperative stress 
target-controlled infusion technology has been used to induce appropriate hypnotic 
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BacKgroUnD: the aim of this study was to evaluate the analgesic potency dose of remifentanil to maintain surgical 
Pleth index (sPi) values at less than 50 after intubation in patients undergoing general anesthesia with target-controlled 
infusion of propofol and remifentanil.
MetHoDs: We randomly allocated 120 patients to receive one of three remifentanil target effect-site concentrations (5, 
7, or 9 ng×ml-1) during intubation. the target effect-site concentrations of propofol were adjusted within a range of 2.5-3 
μg×mL-1 to maintain bispectral index values at less than 60 during anesthesia induction. a reusable sPi sensor was placed 
on the index finger of the arm, and the SPI values were continuously recorded. The predicted probability for maintaining 
the sPi values at less than 50 after intubation against the cumulative amount of remifentanil was analyzed using logistic 
regression. the measurands were the baseline sPi value in patients without pain scheduled for surgery, and the maximal 
sPi value after intubation in patients receiving remifentanil with a target effect-site concentration of 7 ng×ml-1.
resUlts: the estimated cumulative amount of remifentanil associated with a 50% and 95% probability of maintain-
ing the sPi values at less than 50 after intubation were 135.0 µg and 330.4 µg, respectively. the estimated expanded 
uncertainty for the baseline and maximal sPi values after intubation in patients scheduled for surgery were 54.9±44.4 and 
54.1±37.9, respectively, which corresponded to a confidence level of approximately 95%.
conclUsions: the analgesic potency dose of remifentanil to maintain sPi values at less than 50 after intubation was 
135.0 µg.
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algesic potency dose of remifentanil to maintain 
the sPi values at less than 50 after intubation 
in patients scheduled for surgery under target-
controlled infusion with different target effect-
site concentrations of remifentanil. in addition 
to this purpose, the measurement uncertainty of 
the sPi was characterized in patients receiving 
an appropriate target effect-site concentration 
of remifentanil during intubation.
Materials and methods
Patient population
this single-center, prospective, random-
ized, single-blinded, and parallel-arm clinical 
trial was conducted between July and october 
2016. this study was approved by the asan 
Medical centre institutional review Board 
(approval number: 2016-0477) and registered 
on an international clinical trials registry plat-
form (http://cris.nih.go.kr, Kct0002080), and 
written informed consent was obtained from 
all patients. Patients who were between 20 
and 80 years of age and scheduled for elec-
tive surgery were enrolled if their asa physi-
cal status was i or ii. the exclusion criteria 
were as follows: pregnancy or lactation, where 
pregnancy is defined as the state of a woman 
from conception, confirmed by a positive 
urine pregnancy test, until the termination of 
gestation; severely impaired respiratory func-
tion or respiratory depression status; clinically 
significant impairment of cardiovascular, he-
patic, or renal function; risk of gastric aspira-
tion on anesthesia induction; and Mallampati 
Score ≥4. Patients were randomly allocated to 
receive one of three remifentanil target effect-
site concentrations (5, 7, or 9 ng×ml-1) during 
intubation. randomization was performed the 
day before operation using r software (version 
3.1.2, r Foundation for statistical computing, 
vienna, austria).
Study procedure
all patients fasted from midnight. once in 
the operating room, the patients were moni-
tored using electrocardiography, pulse oxim-
caused by nociceptive stimuli is important be-
cause it affects the patient’s treatment outcome 
and length of hospital stay.2, 3 Direct laryn-
goscopy to facilitate orotracheal intubation is 
one of the most severe noxious stimuli evoked 
during general anesthesia.4 such stimuli can 
be managed most effectively by providing an-
algesia.5, 6
the surgical Pleth index (sPi), which was 
developed to quantify intraoperative stress lev-
els, has been shown to reflect noxious stimuli 
better than the heart rate or blood pressure.7-9 
a previous study showed that the sPi was 
significantly correlated to the levels of stress 
hormones, including adrenocorticotropic 
hormone, cortisol, epinephrine, and norepi-
nephrine.10 the sPi-guided analgesia strat-
egy recommends maintaining the sPi values 
at less than 50 during general anesthesia.11, 12 
Previous studies have shown that, compared 
with the standard clinical analgesia practice, 
the sPi-guided analgesia strategy resulted in 
lower remifentanil consumption, more stable 
hemodynamics, and lower incidence of un-
desirable events.11, 13 However, to the best of 
our knowledge, the analgesic potency dose of 
remifentanil to maintain the sPi values at less 
than 50 after intubation has not been evalu-
ated in patients undergoing general anesthesia 
with target-controlled infusion of propofol and 
remifentanil.
Measurement is defined as a process of ex-
perimentally obtaining one or more values that 
can reasonably be attributed to a quantity.14 
generally, a measurement result consists of a 
single measured quantity value and a measure-
ment uncertainty.15 this uncertainty represents 
a parameter characterizing the dispersion of 
the quantity values being attributed to a mea-
surand based on the information used.14 an 
understanding of metrological concepts may 
be helpful when making clinical decisions. For 
example, a bispectral index value of 60 plays a 
role in making a guideline to the clinical doc-
tors on maintaining anesthesia depth. Howev-
er, when taking account of metrological con-
cept, this reference value may be expressed as 
a range not as a single point.
the aim of this study was to evaluate the an-
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mographic amplitude (PPga) and heart beat 
interval (HBi) extracted from the plethysmo-
graphic wave signal of the pulse oximeter,18 
and it was normalised to the range 0-100 by 
using a histogram transformation. sPi= 100 
- (0.7 ∙ PPGAnorm + 0.3 ∙ HBInorm).8, 12, 19 the 
value ranges between 0 (low stress response) 
and 100 (high stress response). a value of 50 
represents a mean stress level during anesthe-
sia, and a range between 20 and 50 has been 
used previously to guide analgesics.11
Determination of analgesic potency dose using 
logistic regression
Patients showing sPi values equal to or 
greater than 50 within 5 min after the start of 
intubation were coded as 0, whereas patients 
showing sPi values less than 50 were coded as 
1, which was considered as an analgesia. the 
relationship between the probability of anal-
gesia and the amount of remifentanil admin-
istered before intubation was analyzed using a 
sigmoid Emax model:
where DoseRemi is the amount of remifentanil 
administered before intubation, DoseRemi50 is 
the amount of remifentanil associated with 
a 50% probability of analgesia, and γ is the 
steepness of the concentration-versus-response 
relationship.
the likelihood ‘l’ of the observed response 
‘r’ is described by the following equation:
L= R ∙ Prob + (1-R) ∙ (1-Prob),
where Prob is the probability of analgesia. 
The logistic regression model was fitted using 
nonMeM® 7 level 3 (icon Development so-
lutions, Dublin, ireland). inter-individual varia-
tions in this model could not be successfully 
estimated with only one observed value per in-
dividual (amount of remifentanil administered 
before intubation). therefore, a naïve-pooled 
data approach was used. Model parameters were 
estimated using the option ‘liKeliHooD la-
Place MetHoD=conditional’ of nonMeM.
etry, end-tidal carbon dioxide partial pressure, 
non-invasive blood pressure, and bispectral 
index (aspect 2000; aspect Medical systems, 
inc., newton, Ma, Usa) measurements. a 
reusable sPi sensor (carescape® B850; ge 
Healthcare, Milwaukee, Wi, Usa) was placed 
on the index finger of the arm opposite to the 
one used for blood pressure measurement. 
neuromuscular transmission was monitored 
using the M-nMt® module at the adduc-
tor pollicis muscle (carescape® B850, ge 
Healthcare, Milwaukee, Wi, Usa). through-
out the surgery, these data were continuously 
downloaded to personal computers by using 
rs232c cables. Following preoxygenation 
with 100% o2, anesthesia was induced with 
propofol and remifentanil, which were ad-
ministered using a target effect-site concentra-
tion-controlled infusion pump (PiontM tci; 
Bionet co., ltd., seoul, republic of Korea) by 
using the models suggested by schnider et al. 
and Minto et al.16, 17 after securing adequate 
mask ventilation, rocuronium (0.6 mg×kg-1) 
was administered intravenously. the target 
effect-site concentrations of propofol were 
adjusted within a range of 2.5-3 μg×mL-1 to 
maintain the bispectral index values at less 
than 60 during the induction and maintenance 
of anesthesia. the target effect-site concentra-
tions of remifentanil were maintained until the 
end of intubation. orotracheal intubation was 
performed by an experienced anesthesiologist 
when a train-of-four count was less than two, 
and a pseudo-steady state of remifentanil be-
tween the blood and brain was achieved. the 
start time of intubation was defined as the time 
of opening the patient’s mouth. after intuba-
tion, the target effect-site concentration of 
remifentanil was changed to 3 μg×mL-1 until 
the start of surgery. if necessary, ephedrine or 
atropine was administered during anesthesia to 
maintain the systolic blood pressure above 80 
mmHg and heart rate above 45 beats×min-1. 
the target effect-site concentrations of remi-
fentanil were titrated to maintain stable hemo-
dynamics (systolic blood pressure > 80 mmHg 
and heart rate > 45 beats×min-1) within the 
range of 3-20 ng×ml-1 during surgery. the sPi 
value was calculated using the photoplethys-
Th
is
 d
oc
um
en
t i
s 
pr
ot
ec
te
d 
by
 in
te
rn
a
tio
na
l c
op
yr
ig
ht
 la
w
s.
N
o 
ad
di
tio
na
l r
ep
ro
du
ct
io
n 
is 
au
th
or
ize
d.
It 
is
 p
er
m
itt
ed
 fo
r 
pe
rs
on
al
 u
se
 to
 d
ow
n
lo
ad
 a
nd
 s
av
e
 o
n
ly 
on
e 
file
 a
nd
 p
rin
t o
nl
y 
on
e 
co
py
 o
f t
hi
s 
Ar
tic
le
.
It 
is
 n
ot
 p
er
m
itt
ed
 to
 m
ak
e
 a
dd
itio
na
l c
op
ie
s
(ei
the
r s
po
rad
ica
lly
 o
r s
ys
te
m
at
ica
lly
,
 
e
ith
er
 p
rin
te
d 
or
 e
le
ct
ro
ni
c) 
of 
the
 A
rtic
le
 fo
r 
a
ny
 p
ur
po
se
.
It 
is
 n
ot
 p
er
m
itt
ed
 to
 d
ist
rib
u
te
 th
e 
el
ec
tro
ni
c 
co
py
 o
f t
he
 a
rti
cl
e 
th
ro
ug
h 
on
lin
e 
in
te
rn
e
t a
nd
/o
r i
nt
ra
n
e
t f
ile
 s
ha
rin
g 
sy
st
em
s,
 
e
le
ct
ro
ni
c 
m
ai
lin
g 
or
 a
ny
 o
th
er
m
e
a
n
s 
w
hi
ch
 m
ay
 a
llo
w
 a
cc
e
ss
 to
 th
e 
Ar
tic
le
.
Th
e 
us
e 
of
 a
ll 
or
 a
ny
 p
ar
t o
f t
he
 A
rti
cl
e 
fo
r 
a
ny
 C
om
m
er
cia
l U
se
 is
 n
ot
 p
er
m
itt
ed
.T
he
 c
re
at
io
n 
of
 d
er
iva
tiv
e
 w
o
rk
s 
fro
m
 th
e 
Ar
tic
le
 is
 n
ot
 p
er
m
itt
ed
.T
he
 p
ro
du
ct
io
n 
of
 re
pr
in
ts
 fo
r 
pe
rs
on
al
 o
r c
om
m
er
cia
l u
se
 is
n
o
t p
er
m
itt
ed
.I
t i
s 
no
t p
er
m
itt
ed
 to
 re
m
ov
e,
 
co
ve
r,
 
ov
e
rla
y, 
o
bs
cu
re
,
 
bl
oc
k,
 o
r c
ha
ng
e 
an
y 
co
py
rig
ht
 n
ot
ice
s 
or
 te
rm
s 
o
f u
se
 w
hi
ch
 th
e 
Pu
bl
is
he
r m
ay
 p
os
t o
n 
th
e 
Ar
tic
le
.
It 
is
 n
ot
 p
er
m
itt
ed
 to
 fr
a
m
e
 o
r 
u
se
 fr
a
m
in
g 
te
ch
ni
qu
es
 to
 e
nc
lo
se
 a
ny
 tr
a
de
m
ar
k,
 lo
go
,
o
r 
o
th
er
 p
ro
pr
ie
ta
ry
 in
fo
rm
a
tio
n 
of
 th
e 
Pu
bl
is
he
r.
                  COPYRIGHT© 2018 EDIZIONI MINERVA MEDICA 
sPi resPonse to intUBation WitH reMiFentanil ParK
vol. 84 - no. 5 Minerva anestesiologica 549
age differences in the baseline and maximal 
sPi values after intubation at target remifen-
tanil effect-site concentrations of 5, 7, and 9 
ng×ml-1 were 19.6, 24.5, and 23.1, respective-
ly, with a pooled sD of 5.8. this study showed 
that a sample size of 41 patients per treatment 
arm would be sufficient to detect the differ-
ences in sPi values with different effect-site 
concentrations, with 90% power at an alpha of 
0.05 and considering a 20% drop-out rate.
a population pharmacodynamic analysis 
was performed with nonMeM vii level 3 
(icon Development solutions, ellicott city, 
MD, Usa) to determine analgesic potency 
dose of remifentanil. a log-normal model 
was used to estimate the inter-individual ran-
dom variabilities (iiv) of pharmacodynamic 
parameters, and diagonal matrices were ap-
plied to estimate the various distributions of 
η, where η represented the IIV. NONMEM 
computed the minimum objective function 
value (oFv), a statistical equivalent to the -2 
log likelihood of the model. An α level of 0.05, 
which corresponds to a reduction in the oFv 
of 3.84 (χ2 distribution, degrees of freedom=1, 
P<0.05), was used to distinguish between hi-
erarchical models. the covariates that were 
analyzed were age, sex, the presence of hy-
pertension, and administration of ephedrine. 
non-parametric bootstrap analysis served to 
validate the models internally.
Statistical analysis
statistical analysis was conducted using 
sigmastat, version 3.5 for Windows (systat 
software, inc., chicago, il, Usa). Differ-
ences of heart rate, systolic blood pressure, 
and sPi between the groups were analyzed 
by using tukey’s test followed by one-way 
analysis of variance (anova) for pairwise 
comparisons. the data including patient char-
acteristics are expressed as the means (sDs) 
for normally distributed continuous variables, 
medians (25-75%) for non-normally distrib-
uted continuous variables, and counts and 
percentages for categorical variables. a P val-
ue less than 0.05 was considered to indicate 
statistical significance.
Uncertainty evaluation of the SPI
the estimation of measurement uncertainty 
was based on the guide to the expression of 
uncertainty in measurement.20 the measur-
ands in this study were the baseline sPi value 
in patients without pain scheduled for sur-
gery, and the maximal sPi value after intuba-
tion in patients receiving remifentanil with a 
target effect-site concentration of 7 ng×ml-1. 
the baseline sPi value was obtained at the 
start of propofol administration. relevant 
sources (xi) of uncertainty evaluated in this 
study were repetitive measurement (xrep) as 
a type-a standard uncertainty, and resolution 
(xres) and calibration of standard (xcal) of the 
sPi as type-B standard uncertainties. the xrep 
was calculated using data from 40 patients al-
located to receive remifentanil with a target 
effect-site concentration of 7 ng×ml-1 during 
intubation. standard uncertainty (us(x)) is the 
uncertainty of the result of a measurement ex-
pressed as a sD. therefore, the standard un-
certainties for each uncertainty source were 
estimated by choosing an appropriate distri-
bution of their values.21 combined standard 
uncertainty (uc(y)) was calculated using the 
equation:
where us(x) is the standard uncertainty and sc 
is the sensitivity coefficient, which denotes the 
uncertainty in (y) arising from the uncertainty 
in (x).20 i means the number of type a and B 
standard uncertainties used in the calculation 
of the combined uncertainty. the method of 
obtaining traceability of sPi is described in 
appendix i.
Statistics
a preliminary study to determine the appro-
priate sample size was conducted by measur-
ing the sPi value of 30 patients allocated to 
receive one of three remifentanil target effect-
site concentrations (5, 7, or 9 ng×ml-1) during 
intubation. in the preliminary study, the aver-
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drawal of consent (N.=2) and difficult intuba-
tion (n.=2). Hence, 120 patients were included 
in the analgesic potency analysis (Figure 1). 
Patient and intubation characteristics are sum-
marized in table i. atropine has not been ad-
ministered to any patient. as the target effect-
site concentration of remifentanil increased, 
the cumulative amount of remifentanil at the 
time of intubation increased significantly, as 
did the number of patients receiving ephedrine 
before intubation. the time courses of the sPi 
5 min before and after the start of intubation 
in patients receiving remifentanil with target 
effect-site concentration-controlled infusion 
of 5, 7, or 9 ng×ml-1 are shown in Figure 2. as 
the target effect-site concentration of remifen-
tanil increased, the maximal value of sPi after 
intubation decreased. Population pharmacody-
namics parameter estimates, inter-individual 
variability, and median parameter values of 
the non-parametric replicates of the logistic re-
gression model of sPi are described in table i. 
on the basis of these results, we calculated the 
predicted probability for maintaining the sPi 
values at less than 50 after intubation, which 
was plotted against the cumulative amount of 
remifentanil (Figure 3). the estimate of the 
cumulative amount of remifentanil associated 
with a 50% (Dose50) and 95% (Dose95) prob-
ability of maintaining the sPi values at less 
Results
Of the 129 patients screened, five were ex-
cluded because they did not meet the inclusion 
criteria. of the remaining 124 patients enrolled 
in this study, four dropped out because of with-
Figure 1.—Consort flow chart of the study. Ce: effect-site 
concentration.
Table I.—Patient and intubation characteristics in three randomized groups.
target effect-site concentration of remifentanil (ng×ml-1) 5(n.=40)
7
(n.=40)
9
(n.=40)
Male/female 10/30 16/24 11/29
age, year 54.1 ± 12.6 53.1 ± 13.6 52.9 ± 12.2
Height, cm 160.7 ± 7.6 161.5 ± 7.6 160.4 ± 6.8
Weight, kg 60.2 (53.7–68.5) 65.8 (55.8–71.0) 61.8 (54.5–66.8)
asa physical status, 1/2 24/16 21/18 25/15
laryngoscopic view of cormack and lehane (i/ii/iii/iv) 18/18/4/0 20/16/4/0 17/20/3/0
cumulative amount of remifentanil at the time of 
intubation, µg
86.5 (82.5-94.2) 130.3 (119.5-145.7)* 164.0 (158.5-182.6)* †
concurrent disease (none/hypertension/diabetes mellitus/
others)
25/9/1/4 28/7/4/1 27/7/2/5
number of patients who received ephedrine before 
intubation
2 1 7†
Data are expressed as mean (sD), median (25-75%), or count as appropriate. Parameters were compared using a one-way analysis of variance 
(ANOVA), Kruskal-Wallis one-way ANOVA on ranks followed by the Tukey Test or χ2 test as appropriate. laryngoscopic view of cormack 
and lehane. grade 1: most of the glottis is seen; grade 2: only the posterior portion of the glottis can be seen; grade 3: only the tip of the 
epiglottis may be seen; grade 4: neither the epiglottis nor the glottis can be seen. others: asthma, hypothyroidism, history of pulmonary 
tuberculosis, or hyperthyroidism.
*P<0.05 versus target effect-site concentration of 5 ng×ml-1; †P<0.05 versus target effect-site concentration of 7 ng×ml-1.
Discontinued 
intervention 
(n.=1)
-  Withdrawal of 
consent
Discontinued 
intervention 
(n.=1)
-  Difficult intuba-
tion
Discontinued in-
tervention (n.=2)
-  Withdrawal of 
consent
-  Difficult intubation
analyzed 
(n.=40)
analyzed 
(n.=40)
analyzed 
(n.=40)
excluded (n.=5)
-  Declined to participate (n.=3)
-  Mallampati score 4 (n.=1)
-  ejection fraction 32% (n.=1)
assessed for eligibility (n.=129)
randomized (n.=124)
remifentanil Ce: 
5 ng ml-1
(n.=41)
remifentanil Ce: 
7 ng ml-1
(n.=42)
remifentanil Ce: 
9 ng ml-1
(n.=41)
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sPi before and after intubation in patients, and 
the distribution of the elapsed time to achieve 
maximal values of heart rate and sPi after the 
start of the intubation are shown in Figures 
4, 5, respectively. overall, it was considered 
appropriate to infuse remifentanil with a tar-
get effect-site concentration of 7 ng×ml-1 for 
minimizing the noxious stress evoked by intu-
bation while avoiding hypotension.
the uncertainty budget of sPi is summarized 
in table iii. the baseline and maximal sPi val-
ues (type-a standard uncertainty) in patients 
allocated to receive remifentanil with a target 
effect-site concentration of 7 ng×ml-1 dur-
ing intubation were 54.9±22.2 and 54.1±18.9, 
respectively. the resolution of the sPi was 
1, and hence, resolution uncertainty was 0.5. 
When converting to standard uncertainty, reso-
lution uncertainty was divided by the square 
than 50 after intubation were 135.0 µg and 
330.4 µg, respectively. in addition, the chang-
es in the heart rate, systolic blood pressure, and 
Figure 2.—time courses of the surgical Pleth index (sPi) during the time period 5 min before and after the start of intubation 
in patients receiving target effect-site controlled infusion of remifentanil at 5 (a), 7 (B), and 9 (c) ng×ml-1. the individual 
(black dotted lines) and mean (red solid lines) values are indicated.
Figure 3.—Predicted probability for maintaining the surgi-
cal Pleth index (sPi) values at less than 50 after intubation 
plotted against the cumulative amount of remifentanil.
Figure 4.—change in heart rate (Hr), systolic blood pressure (sBP), and surgical Pleth index (sPi) before and after intuba-
tion in patients receiving target effect-site concentration-controlled infusion of remifentanil at 5 (a), 7 (B), 9 (c) ng×ml-1. 
Baseline values were obtained at the start of propofol administration.
*P<0.05 versus a target effect-site concentration of 5 ng ml-1; †P<0.05 versus baseline.
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evaluate the traceability of the sPi. the cor-
rection value between the sPi calculated from 
raw PPg and the sPi determined using cares-
cape® B850 was 0.9. generally, calibration un-
certainty is assumed to show a normal distri-
bution and is divided by the coverage factor (k) 
for the given level of confidence. Because the 
95% confidence level calibration uncertainty 
was 0.9, the standard uncertainty of calibration 
was calculated by dividing with the coverage 
factor 2. the estimated expanded uncertainty 
for the baseline and maximal sPi values after 
intubation in patients scheduled for surgery 
were 54.9±44.4 (k=2) and 54.1±37.9 (k=2), 
respectively, which corresponded to a confi-
dence level of approximately 95%.
Discussion
little information is available in the lit-
erature on the analgesic potency dose to re-
duce the surgical stress evoked by intubation 
Figure 5.—Distribution of elapsed time to achieve maximal 
values of the heart rate (Hr) and surgical Pleth index (sPi) 
after the start of intubation in patients receiving target effect-
site concentration-controlled infusion of remifentanil.
*P<0.05 versus heart rate.
Table II.—Population pharmacodynamics parameter estimates (RSE), inter-individual variability (%CV), and me-
dian parameter values (2.5-97.5%) of the nonparametric replicates of the logistic regression model of the Surgical 
Pleth Index (SPI).
Parameter estimate (rse, %) cv (%) Median (2.5-97.5%)
Dose50 135 (6.3) – 135 (116-157)
γ 3.29 (22.7) – 3.33 (1.59-5.07)
nonparametric bootstrap analysis was repeated 2000 times. Dose50 is the cumulative amount of remifentanil associated with a 50% probability 
of maintaining the sPi value at less than 50 after intubation, and γ is the steepness of the concentration-versus-response relationship. inter-
individual variations in this model could not be estimated with only one point per individual. therefore, a naïve-pooled data approach was used.
RSE: relative standard error = SE/mean ∙ 100 (%); CV: coefficient of variance.
Table III.—Uncertainty budget of the Surgical Pleth Index (SPI).
Uncertainty source value type Probability distribution Divisor
sensitivity 
coefficient
standard uncertainty (us(y))
Baseline † Maximum after intubation ‡
repeatability* Baseline † 22.2 a normal (k=1) 1 1 22.2 –
Maximum after intubation ‡ 18.9 – 18.9
calibration of standard 0.9 B normal (k=2) 2 1 0.45
resolution 0.5 B rectangular 1 0.29
combined standard uncertainty, uc (y) 22.22 18.93
Expanded uncertainty (k=2, 95% confidence), U 44.44 37.86
standard uncertainty: uncertainty of the result of a measurement expressed as a standard deviation, type-a standard uncertainty: method of 
evaluation of uncertainty by the statistical analysis of series of observations, type-B standard uncertainty: method of evaluation of uncertainty 
by means other than the statistical analysis of series of observations, combined standard uncertainty: standard uncertainty of the result of a 
measurement when that result is obtained from the values of a number of other quantities, equal to the positive square root of a sum of terms, 
the terms being the variances or covariances of these other quantities weighted according to how the measurement result varies with changes 
in these quantities, Expanded uncertainty: quantity defining an interval about the result of a measurement that may be expected to encompass 
a large fraction of the distribution of values that could reasonably be attributed to the measurand, coverage factor: numerical factor used as a 
multiplier of the combined standard uncertainty in order to obtain an expanded uncertainty, Measurand: quantity to be measured.
*in total, 40 patients were allocated to receive remifentanil with a target effect-site concentration of 7 ng×ml-1 during intubation; †the baseline 
sPi value at the start of propofol administration; ‡the maximal sPi value after orotracheal intubation.
root of 3, assuming a rectangular distribution. 
in total, 7220 instantaneous surgical Pleth 
index (isPi) and sPi data pairs were used to 
: P<0.05 vs. heart rate
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used. a noxious stimulus causes nociception, 
thereby producing a sudden but temporary 
depression of the PPga due to peripheral va-
soconstriction induced by sympathetic activa-
tion.18 The weighting coefficient of PPGAnorm 
was about twice as large as that of HBinorm, in-
dicating that the PPga became a more impor-
tant consideration than HBi when calculating 
the sPi value.
the fundamental idea of uncertainty is a 
relatively new concept in the history of me-
trology, because error analysis has been long 
established in metrology.14 it is now widely 
used in the physiological, biochemical, and 
physical fields when known or suspected el-
ements of error have been assessed and/or 
proper corrections have been applied. the 
important point of uncertainty is that no mea-
surement is exact or certain. it is necessary to 
consider this uncertainty when making a mea-
surement because all kinds of measurements 
have uncertainty. the sources of uncertainty 
could be categorized as type-a or type-B.14 
type-a standard uncertainty is calculated us-
ing statistical analysis of repeated measure-
ments, while type-B standard uncertainty is 
estimated using any other available informa-
tion. if we measure the weight of a patient 10 
times and analyzes the results, this would be 
a type-a standard uncertainty. considering 
the calibration certificate and resolution of a 
scale used for measuring weight would be a 
type-B uncertainty. type-a standard uncer-
tainty and type-B standard uncertainty should 
be each calculated at the coverage factor (k) 
of 1 (k=1). k of 1 means standard deviation 
in general statistics. the two types of standard 
uncertainty are combined to be calculated as 
combined standard uncertainty. expanded 
uncertainty is determined by multiplying by 
the appropriate coverage factor. in general, 
the coverage factor of 2 (k=2) is mainly used, 
which corresponds to a confidence level of ap-
proximately 95%.21
in this study, the contribution of type-B stan-
dard uncertainties of the sPi was negligible 
because type-a standard uncertainty was the 
major contributor, indicating that the sPi val-
ues showed striking inter-individual variabili-
in patients undergoing general anesthesia 
with target-controlled infusion of propofol 
and remifentanil. However, a previous study 
evaluated the mean effect-site concentration 
(5.0 ng×ml-1) of remifentanil for reducing 
cardiovascular responses to tracheal intuba-
tion in 50% of cases, which was determined 
using a modified up-and-down sequential al-
location technique.6 However, the appropriate 
target effect-site concentration of remifentanil 
to minimize the noxious stress evoked by intu-
bation was 7 ng×ml-1 in this study. this dis-
crepancy could be attributed to the differences 
between the target points of the two studies. 
Positive response in the previous study was 
defined as an increase in either the heart rate 
or mean arterial pressure ≥15% of the mean 
values measured 2 min before intubation.6 in 
fact, a mean increase in the heart rate ≥22% of 
the mean values measured 2 min before intu-
bation was observed in the present study. the 
sPi has been known to be a more effective sur-
rogate marker of analgesia than are the heart 
rate or mean arterial pressure.7 although tar-
get effect-site concentration-controlled infu-
sion has been commonly used in clinical situa-
tions, effect-site concentration is not an actual 
value but a simulated value calculated using 
a pharmacokinetic model. the effect-site con-
centration was introduced for collapsing the 
hysteresis loop between plasma concentration 
and effect, and it was calculated using phar-
macokinetic parameters and the blood-brain 
equilibration rate constant (ke0).22 Hence, the 
effect-site concentration varies according to 
the type of pharmacokinetic model and surro-
gate measure of effect used for estimating ke0. 
the dose administered depends on the phar-
macokinetic model and ke0 programmed into 
a target-controlled infusion system even if the 
same target effect-site concentration value 
was maintained during anesthesia. therefore, 
knowing the dose of remifentanil required to 
maintain the sPi value at less than 50 after in-
tubation during anesthesia induction would be 
useful.
the sPi value may have been reaching its 
maximal value earlier than the heart rate does 
after intubation because of the sPi algorithm 
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sPi was the major contributor to the combined 
variance, the estimation of the correction value 
might have little influence on the calculation 
of the combined standard uncertainty.
Conclusions
in conclusion, the analgesic potency dose of 
remifentanil to maintain the sPi values at less 
than 50 after intubation was 135 µg in patients 
undergoing general anesthesia with target-con-
trolled infusion of propofol and remifentanil. 
the authors suggest that this study can con-
tribute to the sPi-guided use of analgesics be-
cause sPi-guided analgesic use during general 
anesthesia is not prevalent in the clinical field. 
Furthermore, more studies will be needed to 
confirm the efficacy of SPI-guided use of anal-
gesics in various anesthetic methods including 
inhalation anesthesia. in addition, considering 
the type-B standard uncertainties of a measur-
and showing a large inter-individual variabil-
ity may not be necessary.
Key messages
 — little is known about the analgesic 
potency of remifentanil to minimize surgi-
cal stress evoked by intubation undergoing 
general anesthesia.
 — the estimated cumulative amount 
of remifentanil associated with a 50% and 
95% probability of maintaining the sPi 
values at less than 50 after intubation were 
135.0 μg and 330.4 μg.
 — the consideration of the type-B stan-
dard uncertainties of a measure and show-
ing a large inter-individual variability may 
not be necessary.
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and interval variations were compensated for 
by suppressing device-related and individual 
variations in order to extract a reliable isPi. 
the distributions of the extracted PPga and 
PPi were assumed normal, because precise es-
timation of PPga and PPi distributions under 
limited sample data remains controversial. the 
cumulative distribution function (cDF) relat-
ed to normal distribution could be calculated 
by estimating the mean and sD of the PPga 
and PPi signals. since the area of the cDF of 
normal distribution was 1, the amplitude and 
interval variations were compensated for by 
mapping them to the cDF output. the maxi-
mum and minimum cDF outputs were bound 
to 1 and 0, respectively, according to the fol-
lowing equation:
where x corresponds to the PPga and PPi val-
ues, and µ, σ, erf, and F(x) are the mean, sD, 
error function (gauss error function), and cDF 
output (normalising function), respectively.
the individual mean and sD of the PPga 
and PPi were estimated using 2-3 min of front 
samples of normal PPg signals, and then the 
group mean and sD were calculated by av-
eraging the individual means and sDs. the 
normalisation of PPga was performed using 
linearly weighted summing of the individual 
PPgas and group PPga. the normalization 
of PPi was performed similarly.
PPGAnormalise = F(0.7 ∙ PPGAindividual + 0.3 ∙ PPGAgroup)
PPInormalise = F(0.7 ∙ PPIindividual + 0.3 ∙ PPIgroup)
ISPI = 100 – (30 ∙ PPInormalise + 70 ∙ PPGAnormalise)
The coefficients of 0.3 and 0.7 in SPI are 
scaled to 30 and 70 to match the normal-
ized range of 0-1 to the percentage range of 
0-100%, respectively. sample-by-sample ap-
plication of the normalised signals was used to 
estimate the isPi, and the sPi was obtained by 
averaging 1 min of the isPi.
Method of obtaining traceability of SPI
We estimated the sPi algorithm by using 
raw photoplethysmographic (PPg) signals 
for establishing its traceability, because the 
manufacturer ge Healthcare did not provide 
any traceability data for the sPi. therefore, 
we calculated a new algorithm, instantaneous 
surgical pleth index (isPi), based on the pho-
toplethysmographic amplitude (PPga) and 
photoplethysmographic pulse interval (PPi). 
to extract the PPga and PPi reliably from 
the PPg signals, which could be contaminated 
by noise, the PPg signal samples acquired at 
a sampling frequency of 300 Hz were filtered 
to obtain smoothed PPg samples while mini-
mising the number of suspicious or distorted 
waveform notches. Zero-phase filtering was 
conducted by applying forward and reverse 
paths of the second order low-pass Butter-
worth filter with a 5-Hz cut-off frequency in 
sequence. then, the PPga and PPi were au-
tomatically extracted from the filtered PPG 
samples. the PPga was derived from the 
abruptly changing slope points, which were 
calculated by squaring the first derivative of 
the PPg samples. the squaring process accen-
tuates the changing slope so that the appropri-
ately defined threshold can regularly extract 
the maximum slope point with respect to one 
period of PPg samples from the squared deriv-
ative samples. From this point, the right-half 
period search window (forward direction) and 
the left-half period search window (reverse 
direction) searched for the maximum and 
minimum points as the peak and trough am-
plitudes, respectively. The PPGA was defined 
as the difference between the peak and trough 
amplitudes. the PPi was the time interval cor-
responding to the number of samples between 
adjacent maximum slope points. the extracted 
PPga and PPi signals could be affected by 
amplitude and interval variations associated 
with differences in PPg devices and indi-
vidual physiology. therefore, the amplitude 
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supplementary Figure 1.—time courses of the sPi during the time period 5 min before and after the start of intubation in 
patients who received ephedrine (a, B, c) and those who did not (D, e, F). Patients received target effect-site concentration 
controlled infusion of remifentanil at 5 (a, D), 7 (B, e), 9 (c, F) ng×ml-1. the individual (black dotted lines) and mean (red 
solid lines) values are indicated.
a
D
B
e
c
F
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